BackAlnylam Pharmaceuticals Overview
Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Target Price

See Alnylam Pharmaceuticals's analyst price targets ($370) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$239.56

Average Target Price

$368.3953.8% upside

18 analysts in the last 4 months

High: $485 | Low: $230

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-08Jefferies$2608.5% upsideOpen
2026-08-28Jefferies$2304% downsideOpen
2026-08-25BernsteinJeffrey Walch$37657% upsideOpen
2026-08-18BMO Capital$31832.7% upsideOpen
2026-08-14Wells FargoDerek Archila$2566.9% upsideOpen
2026-08-04H.C. Wainwright$45589.9% upsideOpen
2026-08-04Truist Financial$31531.5% upsideOpen
2026-08-03BarclaysEliana Merle$45087.8% upsideOpen
2026-07-31Raymond JamesMartin Auster$42075.3% upsideOpen
2026-07-31RBC CapitalLuca Issi$35046.1% upsideOpen
2026-07-31Oppenheimer$35046.1% upsideOpen
2026-07-31Morgan Stanley$30025.2% upsideOpen
2026-07-31Stifel NicolausPaul Matteis$31832.7% upsideOpen
2026-07-13H.C. Wainwright$485102.5% upsideOpen
2026-07-13Truist Financial$41071.1% upsideOpen
2026-07-10Morgan Stanley$40067% upsideOpen
2026-07-09Raymond James$46895.4% upsideOpen
2026-06-29H.C. Wainwright$47096.2% upsideOpen
2026-05-01Morgan Stanley$37054.4% upsideOpen
2026-05-01Bernstein$44786.6% upsideOpen
2026-02-17Canaccord Genuity$42979.1% upsideOpen
2026-02-13Morgan Stanley$36050.3% upsideOpen
2026-02-13Bernstein$45188.3% upsideOpen
2026-02-13Chardan Capital$42577.4% upsideOpen
2026-02-12Stifel NicolausPaul Matteis$44485.3% upsideOpen
2026-01-30H.C. Wainwright$510112.9% upsideOpen
2026-01-20RBC Capital$46594.1% upsideOpen
2026-01-20Wells Fargo$37657% upsideOpen
2026-01-12Needham$529120.8% upsideOpen
2026-01-12Raymond JamesMartin Auster$47297% upsideOpen
2026-01-08Truist Financial$530121.2% upsideOpen
2026-01-06Bernstein$491105% upsideOpen
2025-12-15Leerink PartnersMani Foroohar$35146.5% upsideOpen
2025-12-11Stifel Nicolaus$508112.1% upsideOpen
2025-11-04H.C. WainwrightPatrick Trucchio$570137.9% upsideOpen
2025-10-31Barclays$527120% upsideOpen
2025-10-31OppenheimerLeland Gershell$500108.7% upsideOpen
2025-10-31Chardan CapitalKeay Nakae$47598.3% upsideOpen
2025-10-30UBS$549129.2% upsideOpen
2025-10-30Morgan StanleyMichael Ulz$495106.6% upsideOpen
2025-10-22Cantor Fitzgerald$45087.8% upsideOpen
2025-10-17Truist Financial$535123.3% upsideOpen
2025-10-06Morgan StanleyMichael Ulz$47598.3% upsideOpen
2025-10-06Stifel NicolausPaul Matteis$495106.6% upsideOpen
2025-09-05BMO CapitalKostas Biliouris$47096.2% upsideOpen
2025-07-29Raymond James$37054.4% upsideOpen
2025-07-21Truist FinancialDanielle Brill$38560.7% upsideOpen
2025-06-24BMO CapitalKostas Biliouris$36050.3% upsideOpen
2025-03-21Scotiabank$33841.1% upsideOpen
2025-01-07BernsteinWilliam Pickering$31029.4% upsideOpen

Alnylam Pharmaceuticals (ALNY) FAQ

Alnylam Pharmaceuticals posts a target price of $370. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $370 for ALNY means covering analysts, on average, see the stock 53.8% upside of $239.56 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ALNY's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Alnylam Pharmaceuticals's other metric pages and overview cover the third.

Judging Alnylam Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $370 here, then scan peer and history charts to see if the gap is persistent.